We have previously shown that ICAM-1-deficient mice were resistant to lymphoma dissemination of intravenously injected 164T2 lymphoma cells. Highly aggressive variants of this cell line, however, could overcome this resistance. To discern the complex pattern of gene expression involved in the evolution of aggressiveness in lymphoma cells, we compared the transcriptome of 164T2 cells with that of their aggressive variants using cDNA arrays. We identified several genes that were differentially expressed in nonmetastatic lymphoma cells and their metastatic variants. Galectin-7, associated with the development of chemically induced mammary carcinoma, was one such gene whose expression was significantly upregulated. We showed that it was constitutively expressed in aggressive variants, at both mRNA and protein levels. Galectin-7 expression in aggressive lymphoma cells was induced upon in vivo selection in several organs, including the thymus, the spleen and kidneys. We also showed that treatment of nonaggressive lymphoma cells with 5-aza-2 0 -deoxycytidine was sufficient to induce galectin-7 gene expression. This report is the first to show that galectin-7 is expressed in aggressive lymphoma.
Introduction
The ability of tumor cells to induce the development of metastatic tumors is a multistep process during which genetic and epigenetic events determine the transition from a nonaggressive to an aggressive phenotype. 1 These events will directly impact on several regulatory pathways, most importantly, on tumor cell migration, on cell proliferation, on the balance between cell survival and programmed cell death (apoptosis), on communication with peritumoral cells and with the extracellular matrix, as well as on the establishment of new blood vessels from preexisting vasculature. Identification of the genes expressed at these different stages is thus essential to provide new insights into the molecular mechanisms underlying these biological processes during metastasis. One of the recent developments in experimental molecular biology has been genomic analysis; it allows to survey comprehensively and efficiently the transcription profile of a cell, characteristic of transition to an aggressive phenotype. 2 The intercellular adhesion molecule (ICAM)-1 is an Ig-like cell adhesion molecule expressed by several cell types, including activated leukocytes, some epithelial cells, fibroblasts, and endothelial cells (EC). It can be induced in a cell-specific manner by several inflammatory cytokines, such as TNF-a or IL-1.
3,4 ICAM-1 is a cellular ligand for the membrane-bound integrin receptors LFA-1 and Mac-1 on leukocytes through distinct binding sites. ICAM-1 has significant homology to ICAM-2 and ICAM-3, which also bind LFA-1. However, in contrast to ICAM-1, ICAM-2 is constitutively expressed on EC and lymphocytes, whereas ICAM-3 expression is predominantly found on circulating T cells. Considerable evidence, based on the behavior of LFA-1-deficient mutant lymphoma cells and their revertants, supports a role for LFA-1 in lymphoma metastasis. 5 Using an experimental lymphoma model, we have previously shown that mice bearing mutations in both alleles of the icam-1 gene were resistant to the dissemination of 164T2 lymphoma cells to peripheral organs upon intravenous injection. 6 This gene encodes a cell adhesion molecule (ICAM-1; CD54) expressed on the vascular endothelium. Although ICAM-1 has been shown to be involved in the recruitment of circulating leukocytes at inflammation sites, 7, 8 we found that resistance of ICAM-1-deficient mice was not because of the inability of lymphoma cells to 'home' to the target organ, since they migrated with the same efficiency in both normal and ICAM-1-deficient mice. It seems, rather, that it was at stages subsequent to migration to the target organ that ICAM-1 expression by the host was essential. These results are in fact consistent with the hypothesis that the ability of lymphoma cells to disseminate is manifested at late stages of the metastatic process. [9] [10] [11] Thus, the role of cell adhesion molecules would be to induce, upon binding to their respective ligands expressed at the surface of the lymphoma cells, the expression of new genes necessary for migration and survival of lymphoma cells after homing. 12, 13 This is consistent with the conclusions of our previous study, which showed that aggressive lymphoma variants overcame the resistance of ICAM-1-deficient mice. 14 Since both the 164T2 parental cells and its highly aggressive variants have similar homing properties, we hypothesize that this aggressive behavior is because of the appearance in the variants of a new transcriptome constituted of genes which regulate migration and survival of lymphoma cells after homing. In fact, this notion is supported by our findings that a selective pressure favors the emergence of aggressive lymphoma cells that constitutively expressed mmp-9, a gene previously associated with high-grade lymphomas. 15, 16 Inactivation of several other genes, such as p53 and p16INK4a, by deletions, mutations, and hypermethylation has also been implicated in the development of aggressive variants of lymphoid tumors. [17] [18] [19] In an effort to define the cascade of genetic alterations underlying progression to malignancy, we employed a genetic functional approach to discern from the complex pattern of gene expression those that differ between the aggressive variants and their nonaggressive parental cells. In the present work, we report several genes overexpressed in the aggressive variants. Among those genes whose expression were significantly altered, we further investigated the unexpected and strongly upregulated galectin-7. This gene, originally identified as a keratinocyte marker, 20, 21 has previously been associated with the development of chemically induced mammary carcinoma 22 and is one of the 14 genes previously shown to be under the control of p53. 23 
Materials and methods

Mice
Male and female C57BL/6 were bred in our animal facility and maintained under specific pathogen-free conditions in accordance with institutional guidelines. Breeder pairs for the C57BL/ 6 mouse colony were purchased from Jackson Laboratory (Bar Harbor, ME, USA).
Culture of cell lines
The mouse thymic lymphoma lines 164T2 and 267 were developed in vitro from a radiation-induced thymic lymphoma in C57BL/Ka mice, as previously described. 10 Flow cytometric analysis of these cells, as well as of those of S11 and S19, showed that all cell lines expressed LFA-1, CD31, CD62L, CD90, ICAM-1, ICAM-2, but not a4b1. They all express CD3 and the TcRab, as well as the gp70 and the TL antigen (Lalancette et al, 14 and data not shown). All cell lines were maintained in culture using RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, and 10 mM (N-2-hydroxyethyl-piperazine-N-2-ethane sulfonic acid HEPES) buffer (complete RPMI medium). For treatment with 5-aza-2 0 -deoxycytidine (aza-CdR) (Sigma Chemical Co., St Louis, MO, USA), cells were washed, and aliquots of 1 ml containing 10 6 cells were resuspended in complete medium containing the indicated concentrations of aza-CdR and incubated for 40 h at 371C in a humidified 5% CO 2 atmosphere.
Lymphoid tumour growth
Male or female C57BL/6 mice 4 to 5-week-old were injected in each lobe of the thymus with the indicated number of lymphoma cells. Mice were observed periodically for clinical signs of thymic lymphoma: runting, swelling of the thorax, and dyspnea. When moribund, mice were killed and the presence of thymic lymphoma was confirmed at necropsy. To study lymphoma in peripheral organs, mice at least 6-8 weeks-old were injected with 10 6 lymphoma cells into the tail vein. When clinical signs of lymphoma became evident (dyspnea, runting, and splenomegaly), the animals were killed and the spleen, lungs, ovaries, kidneys, liver and lymph nodes harvested, weighed and fixed in 10% formalin for histologic examination.
In vivo selection of highly aggressive mouse lymphoma cell lines
The aggressive 164T2S11 (S11) and 164T2S19 (S19) cell lines were established from serial in vivo passages (11 and 19 passages, respectively) of the parent 164T2 line in young adult C57BL/6 males using the spleen as the organ from which lymphoma cells were harvested following intravenous injection, as previously described.
14 Clones S11 and S19 are maintained in culture without loss of aggressiveness. The 164T2S3.2 (S3.2) cell line was established following three in vivo passages of the parent 164T2 cells in C57BL/6 spleen, whereas 164T2K3.1 (K3.1) and 164T2K3.2 (K3.2) cell lines were both obtained from three passages of the parent 164T2 line in C57BL/6 kidneys. 
RNA preparation
Atlast mouse 1.2 expression array
All procedures for labelling and purifying the probes were carried out according to the manufacturer's instructions for the Atlast mouse 1.2 cDNA array (Clontech). These cDNA arrays were chosen because transcriptional profiling data obtained from them contain probes specific for known genes from a wide range of biological pathways. Since these could be related to specific biological processes, a clear biological picture can emerge from the model system. The list of genes being tested is available on the web (Clontech.com) with Genbank accession numbers. These broad-coverage Atlas 1.2 arrays were used as they offer the possibility to study the expression profile of many crucial cellular pathways and functions. Briefly, complex [a-
33 P]-dATP-labelled cDNA probes were generated by reverse transcription of mRNA from 164T2 and S19 cells. The probes were purified by column chromatography (NucleoSpin; Clontech) and met the manufacturer's recommendation for specific activity (a total of 12 Â 10 6 cpm for each probe). Hybridization proceeded overnight at 681C in a roller bottle. Membranes were stringently washed with agitation for 30 min of prewarmed (681C) solution 1 (2 Â standard saline citrate (SSC), 1% sodium dodecyl sulfate (SDS)) four times and solution 2 (0.1 Â SSC, 0.5% SDS) once. Subsequently, membranes were rinsed in 2 Â SSC at room temperature, exposed to a phosphor screen for 21 days and scanned (pixel size, 200 mm; PMT voltage, 688 V; local average background correction) using a PhosphoImager SI (Molecular Dynamics, Inc., Sunnyvale, CA, USA). Autoradiographic intensity was measured using ImageQuant software (version 5.0; Molecular Dynamics). Nine housekeeping genes were used as internal control (ubiquitin, phospholipase A2, hypoxantine-guanine phosphoribosyltransferase, glyceraldehyde-3-phosphate dehydrogenase, myosin I, ornithine decarboxylase, -actin, Ca 2+ -binding protein, and ribosomal protein S29). The filters were compared directly without normalization, as expression differences observed for housekeeping genes were not significant (less than 1%) and hybridization was uniformly distributed.
Reverse transcriptase (RT)-PCR
First-strand mouse cDNA was prepared from 1 mg total RNA in a 20 ml reaction volume by random priming using Omniscriptt RT as recommended by the manufacturer (QIAGEN, Mississauga, ON, Canada). In all, 4 ml of the first-strand reaction was used for each PCR reaction with 2.5 U Taq DNA polymerase (QIAGEN). After determining the linear range of RT-PCR for each of the target genes, amplification of the galectin-7 gene was carried out using the following primers: sense 5 0 -CCATGTCTGCTACC-CATCAC-3 0 ; antisense 5 0 -GCTTAGAAGATATTCAATGAATGC-3 0 . A total of 35 cycles of amplification were performed in a thermal cycler (model PTC-100 TM, MJ Research, Watertown, MA, USA) applying the following programmed step cycles: 941C Galectin-7 in lymphoma cells S Moisan et al for 0.5 min, 521C for 1 min, and 721C for 1 min. Then, a final extension step at 721C for 10 min was performed. PCR products were visualized by ethidium bromide staining and UV transillumination. Quantitative analysis was carried out using a computerized densitometric imager (ImageQuant software, version 5.0; Molecular Dynamics). To confirm the identity of the amplicons, an aliquot of the amplified products was ligated into the pCR2.1 vector and INVaF'-competent cells were transformed using the TA Cloning System (Invitrogen, Burlington, ON, Canada) according to the manufacturer's instructions. Positives clones were sequenced bidirectionally.
Western blot analysis
In all, 90 mg of 164T2, S11, S19, and spleen cell lysates were suspended in Laemmli sample buffer (Bio-Rad Laboratories, Mississauga, ON, USA) and subjected to 15% SDS-polyacrylamide gel electrophoresis. After transfer onto 0.45 mm nitrocellulose membrane (Bio-Rad Laboratories), Western blot analysis was performed using a-galectin-7.2 polyclonal antibodies, as described previously.
24
Immunohistochemistry on thymic lymphoma
To study thymic lymphoma, 3-week-old C57BL/6 mice were injected in each lobe with 10 5 S19 cells. At 4 weeks postinoculation, immunodetection of galectin-7 was performed on 5 mm cryostat sections after acetone fixation of thymic lymphoma sections using a-galectin-7.2 polyclonal antibodies. Sections were then treated with horseradish peroxidase-conjugated donkey anti-rabbit Ig (Amersham Biosciences, Baie d'Urfé, QC, Canada) and stained using the aminoethyl carbazole substrate kit according to the manufacturer's instructions (Zymed, San Francisco, CA, USA).
Results
Genomic analysis of gene transcripts in the aggressive variants of nonaggressive lymphoma cells
Our previous results had shown that S19 cells, but not the parental 164T2 cells, could metastasize in otherwise lymphoma-resistant ICAM-1-deficient mice.
14 A total of 1176 known genes were thus tested for their differential expression in both cell lines. This was done using a cDNA array containing PCRgenerated probes specific for murine genes. We found that a very limited number of genes out of the 1176 tested showed a relatively high change in their expression ( Figure 1a and Table 1 ). The most prominent change, however, was the strong upregulation of galectin-7 ( Figure 1b ). This change in aggressive lymphoma was unexpected as galectin-7 is considered a keratinocyte marker expressed in all subtypes of stratified epidermis. 25 The induction of galectin-7 in the aggressive variant S19 was confirmed at the mRNA level by RT-PCR analysis ( Figure 2) . Expression of galectin-7 was also observed in the S11 lymphoma cells, also an aggressive variant of 164T2 cells capable of metastasizing in ICAM-1-deficient mice. DNA sequencing confirmed that the amplicons were galectin-7-specific and that the DNA sequences of the galectin-7 gene in 164T2, S11 and S19 were identical. Comparative analysis of our sequence obtained from lymphoma and the previously published murine galectin-7 sequence 20,21 revealed four differences at the amino-acid level, all located outside the functional galactose-binding domain (GenBank accession number: for mouse lymphoma cells, AF331640; mouse keratinocytes, AF038562). These differences are likely to be because of polymorphism between mouse strains. Alignment of the galectin-7 cDNA sequence isolated from murine lymphoma cells with that of the mouse, human, and rat keratinocyte counterparts shows 98.3, 89.1, and 78.8 % of identity, Expression of galectin-7 at the protein level in freshly isolated tumor cells
In the next series of experiments, we carried out Western blot analysis on 164T2 and S19 cells and showed that S19, but not the parental 164T2 cells, expressed galectin-7 at the protein level (Figure 3a) . To determine whether galectin-7 was expressed at the protein level in vivo in peripheral tumors, dissemination of lymphomas was induced by injecting C57BL/6 intravenously with lymphoma cells. This was an important issue because although our genomic analysis was carried out using aggressive lymphoma cells derived from in vivo passages, the cells had been maintained in culture before comparative genomic analysis. We have previously shown that mice injected 
Figure 2
Expression of galectin-7 in the aggressive variants S11 and S19 lymphoma cells. Lymphoma cells were lysed, RNA extracted, and RT-PCR analysis peformed with galectin-7 and GAPDH primers, respectively, as described in Materials and methods. Results are representative of three independent experiments.
Galectin-7 in lymphoma cells
S Moisan et al with S19 cells develop tumors in spleen (from which tumor cells are easily recovered), kidneys, and liver, but not in the thymus. 14 We found that three out of four splenic lymphoid tumors induced by S19 had elevated levels of galectin-7 ( Figure 3b ). Galectin-7 was not detected in normal spleen. Moreover, Western blot analysis of tumor cells recovered from the spleen of mice injected with 164T2 cells showed that one tumor out of three had an elevated level of galectin-7 expression, indicating that one passage was sufficient to induce galectin-7 expression in these galectin-7-negative cells. Expression of galectin-7 in lymphoma induced by injection of S19 cells was further confirmed by immunohistochemical analysis using galectin-7-specific rabbit polyclonal antibodies (Figure 4a ). Dark staining was typically observed in clusters of cells. No such pattern was observed using a preimmune rabbit serum (Figure 4b ).
Induction of galectin-7 expression in lymphoma cells is independent of tumor microenvironment
To further determine whether upregulation of galectin-7 was not because of a random event but was the result of a selective pressure, we carried out another independent series of in vivo passages with the 164T2 parental cells. In this case, a cell line (S3.2) was established from the spleen after only three in vivo passages. We also generated two other cell lines (K3.1 and K3.2) after three passages where lymphoma cells were recovered for each passage from tumors located in the kidneys. We found that galectin-7 was upregulated in all three cell lines after only three passages, regardless of the organ from which the tumor cells were isolated ( Figure 5) . Moreover, the lymphoid tumors induced by galectin-7-positive variants developed much more rapidly than those induced by 164T2 cells (Table 2 ) (Pp0.001). These findings support the view that galectin-7 is induced at the early stage of progression toward an aggressive phenotype, and further shows that this selection for galectin-7 is not restricted to the splenic microenvironment. We have also confirmed the presence of galectin-7 in several other aggressive lymphoma cells, such as 374T1 lymphoma cells 14 (data not shown), establishing that the induction of galectin-7 was not restricted to the 164T2-derived aggressive variants.
Induction of galectin-7 in nonaggressive lymphoma following treatment with 5-aza-CdR
Major attention has focused on DNA methylation as a possible regulatory mechanism for the expression of a number of genes during malignant processes, as an imbalance in the methylation status of the genome favors reactivation of the promoter of genes involved in different aspects of tumorigenesis. Murine lymphoma cell lines 164T2 were thus treated with the DNA methyltransferase inhibitor 5-aza-CdR. Treatment of the 164T2 lymphoma cells with 5-aza-CdR induced galectin-7 gene expression ( Figure 6 ). The induction of galectin-7 expression was not restricted to these lymphoma cells; indeed treatment of 267 cells, another nonaggressive lymphoma cell line, 14 also triggered the expression of galectin-7.
Discussion
In the present work, using a well-characterized model of lymphoma, we used microarrays to identify galectin-7 as a new gene associated with the evolution of lymphoma toward a metastatic phenotype. Specifically, we showed that (1) galectin-7 is constitutively expressed in aggressive variants of 164T2 cells, at both the mRNA and the protein levels, (2) de novo expression of galectin-7 occurred early during the transition toward an aggressive phenotype, (3) the induction of galectin-7 expression in aggressive variants was not restricted to a specific target organ, as its expression could be induced upon passage of lymphoma cells in the spleen, the thymus, and kidneys, and (4) treatment of lymphoma cells with 5-aza-CdR induced galectin-7 gene expression. This is the first report showing that galectin-7 is expressed in lymphoma cells. 164T2 S11 S19 Figure 3 Expression of galectin-7 at the protein level. (a) Western blot analysis showing galectin-7 expression in 164T2, S11, and S19 cultured cells. Equal amounts of protein (40 mg) were loaded in each lane. In (b), mice were injected with 164T2 or S19 cells. When moribund, mice were sacrificed and lymphoid tumors (thymic lymphomas and lymphoid tumors in the spleen) harvested and subjected to Western blot analysis as described in Materials and methods using specific antigalectin-7 polyclonal antibodies. Expression of galectin-7 in lymphoid tumors induced upon intravenous injections of 164T2 (lanes 2-4) and S19 (lanes 5-8) lymphoma cells is shown. Galectin-7 was undetectable in the spleen of normal mice (lane 1). Results are representative of two independent experiments.
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Genomic analysis has facilitated, over the recent years, the identification of genes or markers associated with specific tumor types or other disease conditions. 26, 27 In lymphomas, for instance, it has been possible to conduct a systematic characterization of gene expression in lymphoid malignancies, allowing the molecular classification of tumors on the basis of gene expression and the identification of new markers for lymphoma subtypes. 28, 29 Using highly aggressive variants derived from cells with low metastatic potential following in vivo passages, genomic analysis has also recently been used to identify Rho as an important gene providing melanoma cells with a metastatic phenotype. 30 DNA arrays have also been used to validate the concept that lymphoid malignancies are derived from cells at discrete stages of normal lymphocyte maturation and that the malignant cells retain the genetic program of the normal cells from which they are derived. 31 Galectin-7 is among the 14 genes out of 7002 genes tested whose expression is induced in the early steps of p53-mediated apoptosis. 23 The magnitude of the increased expression of galectin-7 that we have observed in lymphoma was in the same range as that reported by Polyak in colorectal carcinoma cells following infection of these cells with an adenovector containing a p53 Figure 4 Immunohistochemical staining of galectin-7 on thymic lymphoma induced by injection of S19 cells. At 4 weeks after intrathymic injection of S19 cells of a 3-week-old C57BL/6 mouse, immunodetection of galectin-7 was performed on 5 mm cryostat sections of thymic lymphoma after acetone fixation, using a-galectin-7.2 antibodies (a) or preimmune serum as negative control (b). Results are representative of three independent experiments.
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S Moisan et al cDNA insert. Whether galectin-7 induction results from changes in p53 expression, which has been shown to be involved with the transformation of low-grade lymphomas into more aggressive phenotypes, remains to be tested. Experiments using stable transfectants expressing p53 (wild type and mutated forms of p53) as well as other p53-regulated genes need to be done to further clarify the relation between p53 and galectin-7 in lymphoma cells. While the galectin-7 promoter contains relatively strong transcriptional elements, its very narrow tissue distribution, to date restricted mostly to stratified squamous epithelium and to Hassal's corpuscle in the thymus, suggests that its expression is controlled by strong suppressive factors. DNA methylation of several genes has previously been associated with transformation of normal cells to tumor cells, or with progression of a nonmetastatic phenotype toward a metastatic phenotype. [32] [33] [34] In some instances, it is sufficient for DNA methylation of a single CpG dinucleotide to control the expression of p53. 35 Paradoxically, examination of the human galectin-7 promoter reveals a strong transcriptional potential conferred by the presence of three repeats of the GGGTGG motifs present in the 5'-flanking sequence (Moisan et al, GenBank accession number AY037303). Such motifs are also present in other genes that have very restricted tissue distribution, such as CD43. 36 In this case, DNA methylation around the 5'-region of the CD43 gene drastically reduced transcriptional activity, restricting its tissue-specific expression. While recent studies have often focused on the role of hypermethylation on silencing the expression of tumor suppressor genes, the observation that regional hypermethylation is concomitant with widespread genomic hypomethylation suggests that the imbalance in the methylation status of the genome may fundamentally contribute to tumor progression by favoring the expression of genes involved in tumor progression. 37 This concept is supported by experimental evidence showing that hypomethylation induced by 5-aza-CdR is responsible for the induction of a number of prometastatic genes [37] [38] [39] [40] and thereby increases the aggressiveness of tumor cells, 41 including their ability to form pulmonary metastases. 42 Our results with 5-aza-CdR suggest that DNA methylation may contribute to the upregulation of galectin-7 in lymphoma cells. However, further studies at the promoter level are required to definitively establish whether indeed induction of galectin-7 in aggressive lymphoma cells results from regional hypomethylation.
One of the original aspects of the present work lies in the choice of an experimental model where aggressive variants were generated from parental lymphoma cells that were nonmetastatic in ICAM-1-deficient mice. The aggressive S11 and S19 lymphoma cells could be maintained in culture without the loss of aggressiveness and without the need for feeder layer. This ensured that the genetic changes observed in these cells originated from the tumor cells and not from contaminating peritumoral cells. This allowed easy comparison between parental cells and their aggressive variants, a nearly impossible To induce lymphoma, mice at least 6 to 8-week-old mice were injected via the tail vein with 10 6 lymphoma cells resuspended in 200 ml PBS. When clinical signs of lymphoma became evident (dyspnea, runting, and splenomegaly), the animals were killed and spleen, lungs, ovaries, kidneys, liver and lymph nodes harvested, weighed and fixed in 10% formalin for histologic examination. The data are representative of two independent experiments.
Figure 6
Galectin-7 induction following treatment with 5-azaCdR in lymphoma cell lines. Lymphoma cell lines were maintained in serum-free medium and treated with 100 mM 5-aza-CdR for 40 h. Expression of galectin-7 at the mRNA level was detected by RT-PCR analysis using galectin-7-specific primers. Results are representative of three independent experiments. Galectin-7 in lymphoma cells S Moisan et al task when working with tumor cells isolated from different individuals, or when using different cell lines. Such an approach has been used to establish a link between the expression of genes involved in extracellular matrix assembly or the reorganization of the actin-based cytoskeleton and the metastatic potential of melanomas. 30 In our model, however, it was further possible to determine that induction of galectin-7 was independent of the tumor microenvironment, as we compared metastatic lymphoma cells lines derived from tumors located in the spleen and in the kidneys. Moreover, since S11 and S19 lymphoma cell lines were selected for their ability to overcome the resistance of the otherwise lymphoma-resistant ICAM-1-deficient mice, 14 we will be in a good position, using stable transfectants overexpressing galectin-7, to test whether galectin-7 alone can dictate the growth rate of lymphoma cells, 43 or confer to nonmetastatic lymphoma cells the ability to spread in ICAM-1-deficient mice. In fact, it will be interesting to test whether the selection of galectin-7 that we have observed in aggressive lymphoma cells, such as in S19 and K3.1, can also occur in ICAM-1-deficient mice, as adhesion molecules expressed on EC play a critical role in inducing bidirectional signalling that leads to the expression of genes that confer tumor cells with an aggressive behavior. 44, 45 The role of galectin-7 in cancer has previously been implied in a rat model of chemically induced mammary carcinoma. 22 Galectin-7 was originally identified in the human epidermis and later found to be expressed in all types of stratified epithelial cells in the skin, tongue, esophagus, and Hassal's corpuscles in the thymus. 20, 21, 25 In skin keratinocytes, its expression is rapidly induced following exposure to UV irradiation in association with p53 stabilization, and an increased level of the protein was mainly found in sunburned apoptotic keratinocytes. 24 Indeed, Kuwabara et al 46 have shown that stable transfectants of Hela cells expressing galectin-7 exhibit enhanced sensitivity to apoptosis. Interestingly, these cells also expressed many upregulated genes belonging to distinct categories such as extracellular matrix proteins, tumor antigens, metabolic enzymes, and secreted proteins that could play a significant role in the context of tumor behaviour. We thus hypothesize that highly metastatic variants overexpressing galectin-7 have accordingly evolved toward a state of resistance to the proapoptotic function of galectin-7, while their aggressiveness has emerged from either galectin-7 function itself and/or genes induced upon its presence. The members of the galectin family have been reported to participate in several lymphomagenesis-associated processes. Indeed, galectins have been shown to (1) promote the adhesion of lymphoma cells to vascular EC, 47 (2) promote the proliferation of endothelial cells, 48 (3) induce apoptosis in T leukemia cell lines, 49 (4) mediate homotypic adhesion of tumor cells, 50 and (5) protect tumor cells from Fas-induced apoptosis. 51 Moreover, levels of galectins are elevated in many neoplastic diseases, including lymphomas, in the cases of galectin-3. 52 The role of galectins is highly dependent on the tissue(s) in which they are expressed, and probably on the carbohydrates available in a particular environment. Moreover, the fact that the expression of galectin-7 is low and highly restricted in terms of tissue distribution while being expressed in elevated amounts in tumors independently of the tumor localization makes it an attractive target for antitumoral therapy. Indeed, we have recently confirmed that galectin-7 is expressed in human non-Hodgkin's lymphoma tissues (Moisan et al, unpublished observations). All these data justify further investigations on the role of galectin-7 in aggressive lymphoma cells.
